文献速递胸部肿瘤头颈与中枢神经肿瘤

脑脊液游离DNA作为液体活检在ALK重排非小细胞肺癌软脑膜转移中的临床价值

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-01-17

该研究筛查了2011年9月至2018年2月间291例ALK重排肺癌患者,其中30例(10.3%)诊断为软脑膜转移。对11对脑脊液和血浆样本进行二代测序,发现脑脊液驱动基因检出率81.8%(9/11) vs 血浆45.5%(5/11),p=0.183;脑脊液最大等位基因分数均高于血浆,p=0.009。结论认为脑脊液液体活检比血浆更敏感,可用于检测可靶向变异、刻画耐药机制和监测肿瘤反应。

要点

  • 291例ALK重排肺癌中30例(10.3%)诊断软脑膜转移。
  • 脑脊液驱动基因检出率81.8%(9/11) vs 血浆45.5%(5/11),p=0.183,无显著差异。
  • 脑脊液最大等位基因分数均高于血浆,p=0.009。

核心结论

  • 脑脊液液体活检比血浆液体活检更敏感,可检测可靶向变异、刻画进展时的耐药机制并监测ALK重排NSCLC伴软脑膜转移患者的肿瘤反应。
  • 脑脊液可能成为软脑膜转移中有前景的液体活检介质。

研究设计与样本

  • 回顾性筛选2011年9月至2018年2月在本研究所就诊的ALK重排肺癌患者,共291例。
  • 对11对脑脊液和血浆样本进行二代测序分析。

主要发现

  • 291例ALK重排肺癌患者中30例(10.3%)诊断为软脑膜转移。
  • 脑脊液驱动基因检出率为81.8%(9/11),血浆为45.5%(5/11),p=0.183。
  • 脑脊液最大等位基因分数均高于血浆,p=0.009。
  • 脑脊液中最常突变的两个基因为ALK和TP53。
  • 在阿来替尼耐药后的脑脊液中鉴定出守门基因ALK G1202R和C1156F突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Leptomeningeal metastases (LMs) indicated a poor prognosis in NSCLC. LMs were more frequent in driver gene-mutated patients, and cerebrospinal fluid (CSF) cell-free DNA has shown unique genetic profiles of LM in EGFR-mutated LM. However, studies in patients with ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC with LMs are scarce. METHODS: Patients with lung cancer with ALK rearrangement were screened from September 2011 to February 2018 at our institute. CSF and paired plasma were tested by next-generation sequencing. RESULTS: LMs were diagnosed in 30 (10.3%) of 291 patients with ALK-rearranged lung cancer. A total of 11 paired CSF and plasma samples tested by next-generation sequencing were analyzed. Driver genes were detected in 81.8% of the CSF samples (9 of 11) and 45.5% of the plasma samples (5 of 11) (p = 0.183). The maximum allelic fractions were all higher in CSF than in plasma (p = 0.009). ALK and tumor protein p53 gene (TP53) were the two most frequently mutated genes in CSF. Gatekeeper gene ALK G1202R and C1156F mutations were identified in CSF after resistance to alectinib. Multiple copy number variants were mainly found in CSF, including in EGFR, cyclin D1 gene (CCND1), fibroblast growth factor 3 gene (FGF3), and fibroblast growth factor 4 gene (FGF4). Also found were v-myc avian myelocytomatosis viral oncogene homolog gene (MYC) copy number gains and TP53 and cyclin dependent kinase inhibitor 2A gene (CDKN2A) copy number deletions. Brigatinib seemed to be effective in controlling LM. One case showed that CSF could be used to monitor disease development of LM and longitudinally monitor tumor response. CONCLUSION: Liquid biopsy of CSF is more sensitive than liquid biopsy of plasma to detect targetable alterations, characterizing resistance mechanisms on progression and monitoring tumor response in patients with ALK-rearranged NSCLC with LM. Thus, CSF might be promising as a medium of liquid biopsy in LM.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zheng MM, Li YS, Jiang BY, et al. Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. J Thorac Oncol. 2019. PMID: 30659989. doi:10.1016/j.jtho.2019.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。